In vitro antifungal activity of micafungin (FK463) against dimorphic fungi: Comparison of yeast-like and mycelial forms

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 4, 2003, Pages 1376-1381

  Nakai, Toru ^a,b   Uno, Jun ^a   Ikeda, Fumiaki ^b   Tawara, Shuichi ^b   Nishimura, Kazuko ^a   Miyaji, Makoto ^a  

^a CHIBA UNIVERSITY   (Japan)

^b ASTELLAS PHARMA INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN;

ANTIFUNGAL ACTIVITY; ARTICLE; BLASTOMYCES DERMATITIDIS; COCCIDIOIDES IMMITIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ACTIVITY; DRUG POTENCY; DRUG SENSITIVITY; FUNGUS GROWTH; GROWTH INHIBITION; HISTOPLASMA CAPSULATUM; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCELIUM; NONHUMAN; PARACOCCIDIOIDES BRASILIENSIS; PENICILLIUM MARNEFFEI; PRIORITY JOURNAL; SPOROTHRIX SCHENCKII; YEAST;

ANTIFUNGAL AGENTS; FUNGI; LIPOPROTEINS; MICROBIAL SENSITIVITY TESTS; MYCELIUM; PEPTIDES, CYCLIC;

EID: 0037378071     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.4.1376-1381.2003     Document Type: Article

References (30)

1. Ampel, N. M. 1996. Emerging disease issues and fungal pathogens associated with HIV infection. Emerg. Infect. Dis. 2:109-116.
2. Chandlar, F. W., M. M. McNeil, and L. Kaufman. 1998. Emerging fungal infection: histoplasmosis, phaeohyphomycosis, and sporotricosis, p. 115-144. In A. M. Nelson and C. R. Horsburgh, Jr. (ed.), Pathology of emerging infection 2. American Society for Microbiology, Washington, D.C.
3. Domer, J. E. 1971. Monosaccharide and chitin content of cell walls of Histoplasma capsulatum and Blastomyces dermatitidis. J. Bacteriol. 107:870-877.
4. Drutz, D. J., and M. Huppert. 1983. Coccidioidomycosis: factors affecting the host-parasite interaction. J. Infect. Dis. 147:372-390.
5. Espinel-Ingroff, A. 1997. Clinical relevance of antifungal resistance. Infect. Dis. Clin. N. Am. 11:929-944.
6. Espinel-Ingroff, A. 1998. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol. 36:2950-2956.
7. Georgopapadakou, N. H. 2001. Update on antifungals targeted to the cell walls: focus on β-1,3-glucan synthase inhibitors. Exp. Opin. Investig. Drugs 10:269-280.
8. Goldman, M. 1994. Histoplasmosis: a treatment update. Curr. Opin. Infect. Dis. 7:667-670.
9. Graybill, J. R., L. K. Najvar, E. M. Montalbo, F. J. Barchiesi, M. F. Luther, and M. G. Rinaldi. 1998. Treatment of histoplasmosis with MK-0991 (L-743,872). Antimicrob. Agents Chemother. 42:151-153.
10. Ikeda, F., Y. Wakai, S. Matsumoto, K. Maki, E. Watabe, S. Tawara, T. Goto, Y. Watanabe, F. Matsumoto, and S. Kuwahara. 2000. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candididasis and aspergillosis. Antimicrob. Agents Chemother. 44:614-618.
11. Kanetsuna, F., and L. M. Carbonell. 1971. Cell wall composition of the yeastlike and mycelial forms of Blastomyces dermatitidis. J. Bacteriol. 106:946-948.
12. Kanetsuna, F., L. M. Carbonell, I. Azuma, and Y. Yamamura. 1972. Biochemical studies on the thermal dimorphism of Paracoccidioides brasiliensis. J. Bacteriol. 110:208-218.
13. Kobayashi, G. S., S. J. Travis, M. G. Rinaldi, and G. Medoff. 1990. In vitro and in vivo activities of Sch 39304, fluconazole, and amphotericin B against Histoplasma capsulatum. Antimicrob. Agents Chemother. 34:524-528.
14. Kohler, S., L. J. Wheat, P. Connolly, C. Schnizlein-bick, M. Durkin, M. Smedema, J. Goldberg, and E. Brizendine. 2000. Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model. Antimicrob. Agents Chemother. 44:1850-1854.
15. Lorthlary, O., D. W. Denning, and B. Dupont. 1999. Endemic mycosis: a treatment update. J. Antimicrob. Chemother. 43:321-331.
16. Maesaki, S., M. A. Hossain, Y. Miyazaki, K. Tomono, T. Tashiro, and S. Kohno. 2000. Efficacy of FK463, a (1,3)-β-D-glucan synthase inhibitor, in disseminated azole-resistant Candida albicans infection in mice. Antimicrob. Agents Chemother. 44:1728-1730.
17. Matsumoto, S., Y. Wakai, T. Nakai, K. Hatano, T. Ushitani, F. Ikeda, S. Tawara, T. Goto, F. Matsumoto, and S. Kuwahara. 2000. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis. Antimicrob. Agents Chemother. 44:619-621.
18. Miyaji, M., and K. Nishimura. 1977. Investigation on dimorphism of Blastomyces dermatitidis by agar-implantation method. Mycopathologia 60:73-78.
19. Miyaji, M., and K. Nishimura. 1983. Granuloma formation and killing function of granuloma in congenitally athymic nude mice infected with Blastomyces dermatitidis and Paracoccidioides brasiliensis. Mycopathologia 82:129-141.
20. Nakai, T., J. Uno, K. Otomo, F. Ikeda, S. Tawara, T. Goto, K. Nishimura, and M. Miyaji. 2002. In vitro activity of FK463, a novel lipopeptide antifungal agent, against a variety of clinically important molds. Chemotherapy 48:78-81.
21. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
22. National Committee for Clinical Laboratory Standards. 1998. Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi. Proposed standard M38-P. National Committee for Clinical Laboratory Standards, Wayne, Pa.
23. Pappagianis, D., B. L. Zimmer, G. Theodoropoulos, M. Plempel, and R. F. Hector. 1990. Therapeutic effect of the triazole Bay R 3783 in mouse models of coccidioidomycosis, blastomycosis, and histoplasmosis. Antimicrob. Agents Chemother. 34:1132-1138.
24. Rex, J. H., M. A. Pfaller, J. N. Galgiani, M. S. Bartlett, A. Espinel-Ingroff, M. A. Ghannoum, M. Lancaster, F. C. Odds, M. G. Rinaldi, T. J. Walsh, and A. L. Barry. 1997. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin. Infect. Dis. 24:235-247.
25. San-Blas, G. 1982. The cell wall of fungal human pathogens: its possible role in host-parasite relationships. Mycopathologia 79:159-184.
26. San-Bias, G., A. M. Calcagno, and F. San-Bias. 1993. A preliminary study of in vitro antibiotic activity of saperconazole and other azoles on Paracoccidioides brasiliensis. J. Med. Vet. Mycol. 31:169-174.
27. Sekhon, A. S., A. K. Garg, A. A. Padhye, and Z. Hamir. 1993. In vitro susceptibility of mycelial and yeast forms of Penicillium marneffei to amphotericin B, fluconazole, 5-fluorocytosine and itraconazole. Eur. J. Epidemiol. 9:553-558.
28. Stevens, D. A. 1995. Coccidioidomycosis. N. Engl. J. Med. 332:1077-1082.
29. Tawara, S., F. Ikeda, K. Maki, Y. Morishita, K. Otomo, N. Teratani, T. Goto, M. Tomishima, H. Ohki, A. Yamada, K. Kawabata, H. Takasugi, K. Sakane, H. Tanaka, F. Matsumoto, and S. Kuwahara. 2000. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob. Agents Chemother. 44:57-62.
30. Valle, N. R., M. Rosario, and G. Torres-Blasini. 1983. Effects of pH, temperature, aeration and carbon source on the development of the mycelial or yeast forms of Sporothrix schenckii from conidia. Mycopathologia 82:83-88.